Scienture Holdings Inc (SCNX)

$0.32 0.00 (-1.13%)
Market Cap 13.27M
Revenue (ttm) 430,000.00
Net Income (ttm) -41.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9,653.49%
Debt to Equity Ratio 0.01
Volume 449,000
Avg Vol 3,652,444
Day's Range N/A - N/A
Shares Out 40.63M
Stochastic %K 37%
Beta 3.15
Analysts Strong Sell
Price Target $1.50

Company Profile

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN...

Industry: Pharmaceutical Retailers
Sector: Healthcare
Phone: 800 261 0281
Address:
6308 Benjamin Rd, Suite 708, Tampa, United States
Ottersberger
Ottersberger Apr. 8 at 12:01 PM
$SCNX one great news! And I mean news like Oct last year.
0 · Reply
JackCampbell
JackCampbell Apr. 7 at 12:23 PM
$SCNX probably 4 FDA approved drugs by 2028??!! Besides Arbli and Rezenopy (already approved): SCN-102 (Migraine): NDA filing expected in the second half of 2027 SCN-106 (Thrombosis): BLA filing expected in the second half of 2028
0 · Reply
Pjg1003
Pjg1003 Apr. 7 at 12:11 PM
$SCNX let’s have a day
0 · Reply
Rohtan
Rohtan Apr. 7 at 2:52 AM
$SCNX RS coming soon ?
0 · Reply
BinaryLogic
BinaryLogic Apr. 7 at 12:41 AM
$SCNX [2025FY] The following (attached) summary provides a relatively objective interpretation (IMO) of the Company and its 2025FY financial performance. YoY revenue and margin growth were strong, though I was admittedly expecting a more accelerated market penetration in Q4 (Arbli) than shown. The $(26.3)M non-cash impairment charge was unexpected, and (combined with the revenue underperformance) the primary reason for the decline. That said-the fallout to $0.23-0.28 was an excellent opportunity to start/build/add here (IMO). Multiplier upside from that level if/where the Company can scale Arbli, launch Rezenopy (Q2) and come even close to the market penetration possible on either application over the following 12mo. Liquidity sufficient for 12mo, but the Company needs to drive material revenue growth in the interim. $400M combined market (Rezenopy+Arbli) and even 5-10% penetration more than justifies a multiplier move from this level. https://www.stocktitan.net/news/SCNX/scienture-provides-annual-shareholder-update-outlining-significant-po2swt6300x1.html
0 · Reply
focafoca99
focafoca99 Apr. 6 at 6:33 PM
$SCNX next annual shareholder update is mostly a broad strategy piece, talking up product progress, patents and priorities for the year ahead.
0 · Reply
BEATWALLSTREET
BEATWALLSTREET Apr. 6 at 5:25 PM
$SCNX it's definitely going to a dollar
1 · Reply
JackCampbell
JackCampbell Apr. 6 at 1:50 PM
$SCNX "Our portfolio currently includes two FDA-approved products and three pipeline candidates targeting large and growing markets, including migraine, thrombosis, and post-operative pain.......SCN-102 (Migraine): NDA filing expected in the second half of 2027....SCN-106 (Thrombosis): BLA filing expected in the second half of 2028"
0 · Reply
Pjg1003
Pjg1003 Apr. 6 at 1:41 PM
$SCNX got potential!
0 · Reply
JackCampbell
JackCampbell Apr. 6 at 1:33 PM
$SCNX "We fully repaid legacy debt obligations, funded our working capital needs, and strengthened our balance sheet. As of year-end, the company had approximately $6.7 million in cash and positive working capital of approximately $5.2 million, providing an estimated 12-month runway to support ongoing operations and growth initiatives while preserving financial flexibility.........Our portfolio currently includes two FDA-approved products and three pipeline candidates targeting large and growing markets, including migraine, thrombosis, and post-operative pain."
1 · Reply
Latest News on SCNX
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update

Mar 30, 2026, 8:07 AM EDT - 9 days ago

SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update

SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions

Mar 11, 2026, 8:05 AM EDT - 4 weeks ago

SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Feb 3, 2026, 8:05 AM EST - 2 months ago

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment

Jan 14, 2026, 8:05 AM EST - 3 months ago

SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

Dec 22, 2025, 8:05 AM EST - 3 months ago

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Dec 10, 2025, 8:05 AM EST - 4 months ago

SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025

Dec 2, 2025, 8:05 AM EST - 4 months ago

SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025

SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update

Nov 13, 2025, 8:05 AM EST - 5 months ago

SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update

SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

Nov 4, 2025, 8:05 AM EST - 5 months ago

SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

Oct 23, 2025, 8:05 AM EDT - 5 months ago

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

SCIENTURE'S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Oct 16, 2025, 9:00 AM EDT - 6 months ago

SCIENTURE'S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Wellgistics Health Announces Executive Management and Board Changes

Oct 13, 2025, 8:00 AM EDT - 6 months ago

Wellgistics Health Announces Executive Management and Board Changes

WGRX

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Sep 16, 2025, 8:05 AM EDT - 7 months ago

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

Aug 14, 2025, 9:00 AM EDT - 8 months ago

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Aug 13, 2025, 8:05 AM EDT - 8 months ago

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Jul 24, 2025, 5:12 PM EDT - 9 months ago

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Jul 16, 2025, 8:15 AM EDT - 9 months ago

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Scienture Holdings Announces Cancelation of ELOC

Jun 17, 2025, 8:05 AM EDT - 10 months ago

Scienture Holdings Announces Cancelation of ELOC

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

May 28, 2025, 7:45 AM EDT - 11 months ago

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

WGRX

SCIENTURE Announces Executive Leadership Transition

May 22, 2025, 8:05 AM EDT - 11 months ago

SCIENTURE Announces Executive Leadership Transition

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

May 19, 2025, 8:05 AM EDT - 11 months ago

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

Apr 22, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Apr 8, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

Apr 3, 2025, 8:26 AM EDT - 1 year ago

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Mar 25, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

Mar 19, 2025, 8:05 AM EDT - 1 year ago

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

Mar 18, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Mar 6, 2025, 7:40 AM EST - 1 year ago

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Jan 21, 2025, 8:05 AM EST - 1 year ago

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Dec 17, 2024, 8:05 AM EST - 1 year ago

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

Dec 10, 2024, 8:05 AM EST - 1 year ago

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

Sep 24, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

Sep 20, 2024, 11:59 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

Aug 5, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

Jul 26, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

TRxADE Health, Inc. Announces Special Cash Dividend

Jul 9, 2024, 8:05 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Special Cash Dividend

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

May 29, 2024, 4:05 PM EDT - 2 years ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Apr 23, 2024, 4:05 PM EDT - 2 years ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Trxade health, Inc files its 3Q 10Q

Jan 17, 2024, 9:07 AM EST - 2 years ago

Trxade health, Inc files its 3Q 10Q

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

Nov 29, 2023, 6:13 PM EST - 2 years ago

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Oct 17, 2023, 8:05 AM EDT - 2 years ago

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Oct 12, 2023, 8:05 AM EDT - 2 years ago

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

Oct 4, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.

Sep 7, 2023, 9:00 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market

Sep 6, 2023, 9:45 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market

Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand

Aug 24, 2023, 8:05 AM EDT - 2 years ago

Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand

Superlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc.

Aug 22, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc.

TRxADE HEALTH, Inc. Announces Extension of Form 10-Q Filing

Aug 14, 2023, 10:25 AM EDT - 2 years ago

TRxADE HEALTH, Inc. Announces Extension of Form 10-Q Filing

Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team

Aug 3, 2023, 9:05 AM EDT - 2 years ago

Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team

TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m.

Jul 31, 2023, 4:15 PM EDT - 2 years ago

TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m.

Ottersberger
Ottersberger Apr. 8 at 12:01 PM
$SCNX one great news! And I mean news like Oct last year.
0 · Reply
JackCampbell
JackCampbell Apr. 7 at 12:23 PM
$SCNX probably 4 FDA approved drugs by 2028??!! Besides Arbli and Rezenopy (already approved): SCN-102 (Migraine): NDA filing expected in the second half of 2027 SCN-106 (Thrombosis): BLA filing expected in the second half of 2028
0 · Reply
Pjg1003
Pjg1003 Apr. 7 at 12:11 PM
$SCNX let’s have a day
0 · Reply
Rohtan
Rohtan Apr. 7 at 2:52 AM
$SCNX RS coming soon ?
0 · Reply
BinaryLogic
BinaryLogic Apr. 7 at 12:41 AM
$SCNX [2025FY] The following (attached) summary provides a relatively objective interpretation (IMO) of the Company and its 2025FY financial performance. YoY revenue and margin growth were strong, though I was admittedly expecting a more accelerated market penetration in Q4 (Arbli) than shown. The $(26.3)M non-cash impairment charge was unexpected, and (combined with the revenue underperformance) the primary reason for the decline. That said-the fallout to $0.23-0.28 was an excellent opportunity to start/build/add here (IMO). Multiplier upside from that level if/where the Company can scale Arbli, launch Rezenopy (Q2) and come even close to the market penetration possible on either application over the following 12mo. Liquidity sufficient for 12mo, but the Company needs to drive material revenue growth in the interim. $400M combined market (Rezenopy+Arbli) and even 5-10% penetration more than justifies a multiplier move from this level. https://www.stocktitan.net/news/SCNX/scienture-provides-annual-shareholder-update-outlining-significant-po2swt6300x1.html
0 · Reply
focafoca99
focafoca99 Apr. 6 at 6:33 PM
$SCNX next annual shareholder update is mostly a broad strategy piece, talking up product progress, patents and priorities for the year ahead.
0 · Reply
BEATWALLSTREET
BEATWALLSTREET Apr. 6 at 5:25 PM
$SCNX it's definitely going to a dollar
1 · Reply
JackCampbell
JackCampbell Apr. 6 at 1:50 PM
$SCNX "Our portfolio currently includes two FDA-approved products and three pipeline candidates targeting large and growing markets, including migraine, thrombosis, and post-operative pain.......SCN-102 (Migraine): NDA filing expected in the second half of 2027....SCN-106 (Thrombosis): BLA filing expected in the second half of 2028"
0 · Reply
Pjg1003
Pjg1003 Apr. 6 at 1:41 PM
$SCNX got potential!
0 · Reply
JackCampbell
JackCampbell Apr. 6 at 1:33 PM
$SCNX "We fully repaid legacy debt obligations, funded our working capital needs, and strengthened our balance sheet. As of year-end, the company had approximately $6.7 million in cash and positive working capital of approximately $5.2 million, providing an estimated 12-month runway to support ongoing operations and growth initiatives while preserving financial flexibility.........Our portfolio currently includes two FDA-approved products and three pipeline candidates targeting large and growing markets, including migraine, thrombosis, and post-operative pain."
1 · Reply
Pjg1003
Pjg1003 Apr. 6 at 1:22 PM
$SCNX
1 · Reply
djp70
djp70 Apr. 6 at 1:10 PM
$SCNX $ They are filing for a 180 extension for Nasdaq compliance. Per press release posted on Yahoo finance.
1 · Reply
Stock_Catcher
Stock_Catcher Apr. 6 at 12:05 PM
$SCNX Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
1 · Reply
Pjg1003
Pjg1003 Apr. 2 at 6:28 PM
$SCNX let’s have a power hour ehhhh?🙏
0 · Reply
Ottersberger
Ottersberger Apr. 2 at 6:08 PM
$SCNX I don't want to be the spoilsport, but no one shares the thought with me?
2 · Reply
Pjg1003
Pjg1003 Apr. 2 at 3:20 PM
$SCNX wow a few big buys would send this thing
0 · Reply
Pjg1003
Pjg1003 Apr. 2 at 2:45 PM
$SCNX
0 · Reply
Diverstj981
Diverstj981 Apr. 2 at 2:05 PM
$SCNX Hey, give the management team some credit here! They've managed to maintain .57% of he share price over the past 5 years. Talk about abundant evidence of incompetence and poor leadership....🤦
1 · Reply
Ottersberger
Ottersberger Apr. 1 at 6:17 PM
$SCNX I hope not they tried to drive up the price today to then promise us today in the AH that the RS will take effect on Monday....
0 · Reply
JeffersonManvone
JeffersonManvone Apr. 1 at 3:34 PM
$SCNX no seller for now.
0 · Reply
Pjg1003
Pjg1003 Apr. 1 at 2:48 PM
$SCNX this running to a dollar would be a hilarious April fools joke!
1 · Reply
Pjg1003
Pjg1003 Apr. 1 at 1:32 PM
$SCNX sprinkle a little volume and this things going
0 · Reply